Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Resolution of CRL Manufacturing issues in progress - Type A meeting requested
No clinical safety or efficacy concerns raised by FDA
MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the first quarter ended March 31, 2025. The Company also announced the submission of a meeting request to the U.S. Food and Drug Administration (FDA) as the next step in the resolution of CRL issues.
'Our immediate priority is to engage with the U.S. FDA in order to address the CMC-related issues raised in the CRL received for CARDAMYST as a treatment for PSVT,' said Joe Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. 'We are confident we can work with the FDA to fully respond to the CRL and remain committed to the potential of CARDAMYST. If approved, it will be the first and only self-administered therapy for the rapid termination of episodes of PSVT.'
First Quarter and Recent Program Updates
Etripamil for Patients with PSVT
Etripamil for patients with atrial fibrillation with rapid ventricular rate (AFib-RVR)
First Quarter 2025 Financial Results
For further details on the Company's financials, refer to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC.
About Etripamil
Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid response therapy for patients thereby bypassing the need for immediate medical oversight. If approved, etripamil is intended to provide health care providers with a new treatment option to enable on-demand care and patient self-management. This portable, self-administered treatment may provide patients with active management and a greater sense of control over their condition. CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, is well studied with a robust clinical trial program that includes a completed Phase 3 clinical-stage program for the treatment of PSVT and Phase 2 trial for the treatment of patients with AFib-RVR.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company's focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'believe,' 'continue,' 'could,' 'demonstrate,' 'designed,' 'develop,' 'estimate,' 'expect,' 'may,' 'pending,' 'plan,' 'potential,' 'progress,' 'will', 'intend' and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding: the outcomes of future interactions with the FDA, including the potential Type A meeting; Milestone's ability to address the issues raised in the CRL on a timely basis, if at all; the outcome of the potential NDA resubmission; CARDAMYST's potential as a novel treatment option to help patients with PSVT; potential protections afforded by U.S. patents; CARDAMYST's ability to make the biggest difference in patient health, as compared to other available treatment options; the timing of patient enrollment in the Phase 3 study of etripamil for AFib-RVR; and other statements not related to historical facts. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether our future interactions with the FDA will have satisfactory outcomes; whether and when, if at all, our NDA for etripamil will be approved by the FDA; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone's filings with the U.S. Securities and Exchange Commission (SEC), including in its annual report on Form 10-K for the year ended December 31, 2025 and its quarterly report on Form 10-Q for the quarter ended March 31, 2025, in each case under the caption 'Risk Factors,' as such discussions may be updated from time to time by subsequent filings Milestone may make with the SEC. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contact:
Kim Fox, Vice President, Communications, [email protected]
Investor Relations
Kevin Gardner, [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
44 minutes ago
- Business Upturn
Eternal shares in focus today after Blinkit's food licence suspended by Maharashtra FDA in Pune
By Aditya Bhagchandani Published on June 10, 2025, 09:04 IST Shares of Eternal Ltd. were in focus on Tuesday after reports emerged that Maharashtra's Food and Drug Administration (FDA) had suspended the food license of Blinkit in Pune's Balewadi area due to multiple regulatory violations, as reported by The Economic Times . According to the report, a June 5 investigation by the Maharashtra FDA revealed that the Blinkit-operated facility, managed by M/s Energy Darkstore Services near Mitcon College in Balewadi, lacked a valid Food Safety and Standards Authority of India (FSSAI) license required for producing, distributing, or selling food items. In addition to licensing gaps, serious food safety lapses were observed, including improperly stored food items on the floor and missing pest control audits. The FDA acted under Section 31(1) of the Food Safety and Standards Act, 2006, suspending the facility's food business licence until the proper authorisation is obtained. This action follows rising scrutiny of dark store operations across India amid growing concerns over food hygiene and regulatory compliance. Blinkit has not yet responded to queries regarding the suspension. The development has sparked renewed market attention toward Eternal Ltd., which is believed to have exposure or links to service providers in the last-mile and food retail space. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Medscape
2 hours ago
- Medscape
Part D Cancer Drug Launch Prices Soar Past Inflation
Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.
Yahoo
3 hours ago
- Yahoo
COVID Crusader Writes Open Letter To RFK Jr On mRNA
A prominent group of health activists is threatening a political revolt against HHS Secretary Robert F. Kennedy Jr. over what they call a betrayal of their movement's central cause. In a blistering open letter dated June 4, COVID crusader Dr. Mary Talley Bowden and several allies from the MAHA (Make America Healthy Again) movement — a grassroots coalition of vaccine-critical and medical freedom activists — accused Kennedy and FDA Commissioner Dr. Marty Makary of watering down policies related to the controversial mRNA vaccine platform, especially in guidance affecting children and pregnant women. 'We did not fight for you to be in positions of leadership so that our clearly stated policy goals would suffer a 'bait and switch,'' Bowden wrote, warning Kennedy that MAHA voters 'can walk away' if their demands are not met. The letter criticizes recent CDC and FDA policy changes, calling them deceptive and insufficient, and claims the administration is engaging in 'linguistic misdirections' to hide the continued recommendation of mRNA shots for vulnerable populations. The MAHA letter insists the mRNA platform — particularly COVID vaccines — should be pulled from the market entirely, citing adverse event data and peer-reviewed studies. It demands sweeping reforms: a full ban on mRNA technologies, repeal of the PREP Act, elimination of vaccine-related conflicts of interest in federal agencies, and an end to direct-to-consumer pharmaceutical advertising. The signatories include author Naomi Wolf, podcaster Shannon Joy, and several other activists who rose to prominence during the COVID-19 pandemic by challenging government vaccine narratives. The backlash comes amid growing scrutiny of RFK Jr.'s recent actions as HHS secretary. Once one the nation's most vocal mRNA vaccine skeptic, Kennedy has walked a careful line in office, telling Congress in May that his personal views on vaccines are 'irrelevant' and vowing not to make sudden changes to CDC policy. 'I don't think people should be taking medical advice from me,' Kennedy told lawmakers, as reported by The Hill on June 2. Still, his critics on both sides see Kennedy's recent moves as consequential. Late last month, he released a 58-second video on X stating that COVID vaccines for healthy children and healthy pregnant women had been removed from the CDC's immunization schedule — a declaration Bowden and others say was misleading. Indeed, as The Hill previously reported, the CDC quietly changed its guidance to say healthy children may receive the COVID vaccine after consultation with a healthcare provider, while maintaining stronger recommendations for other vulnerable categories. For pregnant women, the recommendation was similarly softened but not eliminated, and pregnancy remains classified by the FDA as a high-risk health condition, allowing continued vaccine use under certain circumstances. Bowden's letter zeroes in on this ambiguity, arguing that wordplay is being used to sustain vaccine availability under the appearance of reform. 'Pregnant women have not been made any safer by your wordplay,' she writes, warning that MAHA activists are prepared to run their own candidates in upcoming elections if their demands are ignored. The political threat underscores the friction between Kennedy and the movement that once celebrated his nomination. While Kennedy has taken steps to reshape HHS in ways consistent with his skepticism — including canceling hundreds of millions of dollars in funding for Moderna's mRNA flu vaccine— his first few months of actions have not thus far rendered the swift action that some would have hoped. Former CDC acting director Dr. Richard Besser and other public health experts have voiced alarm at Kennedy's willingness to circumvent the CDC's vaccine advisory panel, which has traditionally guided immunization policy through public, evidence-based deliberation. 'We're seeing a total side-stepping of the nation's leading public health agency,' Besser told The Hill. The vaccine panel has not yet weighed in on the updated COVID shot guidance. Its next meeting is scheduled for late June, and observers expect tense debate over whether Kennedy's changes represent science-based reform or political overreach. In the meantime, Bowden's warning reflects the fragile coalition Kennedy is attempting to hold together. The MAHA movement — built in part from disaffected MAGA voters, vaccine skeptics, and parents concerned about government overreach — played a pivotal role in rallying support for Kennedy's confirmation and the broader medical freedom agenda. Now, its leaders are openly questioning whether Kennedy's tenure will deliver the systemic change they demand — or whether they were simply used to fuel a political ascent. 'MAHA is not the possession of Secretary Kennedy,' Bowden wrote. 'It is the voice of millions of desperate parents… and their activism will outlast any administration.' The Dallas Express reached out to HHS but did not immediately receive a response. Kennedy previously spoke to The Dallas Express about a lawsuit Bowden brought against the FDA for misleading the public about using ivermectin for the treatment of COVID-19 during his presidential campaign in 2024 and just after the FDA settled the case. 'All three of the principal health agencies [CDC, NIH, FDA] suffer from agency capture,' Kennedy said. 'I would say 50% of the FDA's budget is from pharmaceutical companies. NIH scientists are allowed to collect royalties on drugs that they regulate –– which is clearly a conflict of interest. CDC … has devolved into an agency that primarily promotes the mercantile interests of the pharmaceutical companies.' He told DX that the agencies are overly influenced by perverse incentives from the pharmaceutical industry and added, 'I will change those incentives and unravel the culture of corruption that now has turned these agencies against public health.'
